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INTRODUCTION
In the UK, incidence rates of breast cancer reported by the
National Cancer Intelligence Centre at the Office for National
Statistics (ONS; formerly the Office of Population Censuses and
Surveys) among women aged 50–64 increased after 1988 (Quinn
and Allen, 1995) when widespread mammographic screening of
women in this age range was introduced (Department of Health
and Social Security, 1986).
The General Practice Research Database (GPRD) has been used
extensively in pharmacoepidemiologic studies of cancer and other
illnesses (Walley and Mantgani, 1997; Jick, 1997). We estimated
the age-adjusted annual incidence rates of breast cancer in women
aged 35–69 during the years 1990–1996 in the GPRD and
compared these rates to those from the ONS (Quinn et al, 1999).
MATHERIALS AND METHODS
Detailed descriptions of the cancer registration system in the UK
have been published elsewhere (ONS, 1999; Quinn and Allen,
1995).
The General Practice Research Database (GPRD) contains
records for some 3 million people in the UK. All clinical data from
the GPRD are provided to the researchers with patients identified
only by unique numbers. We selected for study all 263 practices
that had been continuously active since their date of entry into the
GPRD and had updated their data to the end of September 1997.
None of the practices contributing data to this study joined the
GPRD after 1993.
Cases were identified by three selection processes and then
confirmed (or otherwise) by review of computer records. The first
was to select records of women who had a first-time diagnostic
code for breast carcinoma. The second was to select records of
women who were prescribed tamoxifen for the first time in a given
year but did not have a specific diagnosis of breast carcinoma.
Finally, we selected records of women with a set of characteristics
(mastectomy or breast lump or biopsy followed within 6 months
by a recorded diagnosis of carcinoma (type unspecified) or radia-
tion therapy) which indicated that she may have had breast cancer
even if the diagnosis was not recorded and tamoxifen was not
prescribed.
We then reviewed the computer records of all women selected
by the above process to determine whether each was an incident
case of breast carcinoma. For a woman to be confirmed as an inci-
dent case, we required that she have a breast lump or mammo-
graphic abnormality recorded immediately before the diagnosis of
breast cancer, and a subsequent mastectomy, lumpectomy, or fine
needle aspiration with comments indicating a finding of cancer.
We also included cases in the absence of the above criteria if the
diagnosis of breast cancer was followed by the initiation of
chemotherapy or radiation therapy or if there were other
comments recorded that justified identifying the case as incident.
We excluded women with a history of breast cancer before the
study period. Only confirmed cases were analysed further.
Although there is no distinct diagnostic code for breast carcinoma
in situ, this histology was noted in free text comments in approxi-
mately 5% of records of women aged 50–64.
We classified confirmed incident breast cancer cases by year of
diagnosis, by age at diagnosis and by geographic region. Crude
and age-specific annual incidence rates were calculated using the
total number of women registered in the GPRD during each year
of the study. Directly age standardized incidence rates were calcu-
lated using the European standard population (dos Santos Silva,
1999). Statistical calculations were performed using Stata version
6.0 (Stata Corp., College Station, TX).
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RESULTS
From 1990 to 1996, 417 891 women aged 35 to 69 contributed a
total of 2 181 296 woman-years. We found 4248 incident cases of
breast cancer. 3935 (93%) women had a coded diagnosis of breast
carcinoma recorded in the GPRD for the first time during one of
these years. An additional 266 (6%) women without a diagnosis of
breast carcinoma were prescribed tamoxifen for the first time
during the study and were found to be incident cases of breast
cancer upon review of their computer records. Among women
who neither had a diagnosis of breast carcinoma nor received
tamoxifen, 47 (1%) had a mastectomy or either a breast lump or
biopsy followed within 6 months by either a diagnosis of carci-
noma (unspecified type) or radiation therapy and were considered
to be incident cases of breast cancer.
GPRD breast cancer incidence rates increased with increasing
age among women aged 35–39, 40–44, 45–49 and 50–54
(Figure 1A). ONS data show the same patterns (Figure 1B).
However, the incidence rates for women aged 55–59 in the GPRD
were higher than the rates for women aged 65–69 from 1990 to
1993, and the incidence rates for women aged 60–64 were
higher than the rates for women aged 65–69 in every year of the
study. The ONS data are similar in that incidence rates among
the age groups targeted for screening (50–64) were similar to or
higher than those for women aged 65–69 during most years of the
study (Figure 1B). There was a sustained increase in incidence
among women aged 50–54 in both the GPRD and ONS data
(Figures 1A, 1B).
The directly age standardized breast cancer incidence rates from
the GPRD and the ONS data are shown in Figure 2; the rates are
similar throughout the period, except that the GPRD rates for 1991
and 1994 are significantly higher than the ONS rates. Both the
GPRD and ONS data suggest a decrease in incidence rates in 1993
but the changes are not statistically significant.
The annual incidence of breast cancer was examined for 11
areas of the UK (the 8 health regions of England, Wales, Scotland
and Northern Ireland). In a Poisson regression model adjusting for
age, the incidence of breast cancer was not significantly different
among the 11 regions (results not shown).
DISCUSSION
Our study found that breast cancer incidence rates among women
aged 35–69 in the GPRD were closely similar to those reported by
the ONS. The slightly higher incidence rates in the GPRD in some
years of the study are probably due to the inclusion in the GPRD of
in situ carcinomas, while the ONS data include only invasive
cancers. The higher incidence rates for women aged 55–59 and
60–64 compared with women aged 65–69 are likely to be due to
the NHS Breast Screening Programme.
Although the initial round of mammographic screening was
planned to take place in the UK from 1988 to 1991, the acceptance
rate for screening across the UK averaged 71%, and only 72% of
screening programmes reached the target 70% acceptance rate
(Chamberlain et al, 1993). Because some slippage in the screening
programme schedule also occurred (Faux et al, 1998), incidence
rates in 1991 among women invited for screening were still
increasing. Increases in incidence among women aged 50–54
relative to those aged 55–59 may have resulted from depletion of
screen-detectable tumours among the older screened women and
continued entry into the study population of newly screened
women aged 50–54.
Only a few small studies have provided validation of results
from the UK cancer registries, and only a small number of breast
cancers have been included in these studies (Huggett, 1995;
Brewster et al, 1997). In one study in the mid-1980s, only 36 of 50
(72%) cases of breast cancer in a cohort of 4544 taking hormone
replacement therapy had been included in the national registry
system (Hunt and Coleman 1987). In another report, 138 of 150
(92%) breast cancers reported to investigators of the Oxford-FPA
contraceptive study were registered (Villard-Mackintosh et al,
1988). In a more recent study, 535 of 599 (89%) breast cancers
diagnosed at one hospital in the Trent region were registered
within one year (Stotter et al, 2000).
Although protection of personal identity in the GPRD precludes
identification of the subjects diagnosed with breast cancer and
direct comparison with cancer registry data, the close similarity of
incidence rates between the GPRD data and recent ONS data
(Quinn et al, 1999), the generally low proportion of cases recorded
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Figure 1 Age-specific incidence rates by year of diagnosis in the GPRD (A)
and ONS data (B). The NHS Breast Cancer Screening Programme targeted
women in the age groups indicated by dashed lines (50–54, 55–59, and
60–64).
Figure 2 GPRD and ONS breast cancer incidence rates among women
aged 35–69 directly standardized to the European standard population. Error
bars indicate 95% confidence intervals for the GPRD rates.1558 JA Kaye et al
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solely from the information on a death certificate (Parkin et al,
1994), and the coherence of the national data on incidence,
mortality, and survival all provide evidence that the GPRD and the
national registration data are similarly, and substantially, complete.
The GPRD data are updated annually and can be used to confirm
national trends in cancer incidence at relatively low cost because
they are already being collected to document ongoing medical
care.
While continuation of dedicated cancer registration systems
remains vital to cancer control and public health, large-scale
medical databases such as the GPRD can also provide timely and
accurate information on cancer incidence. The richness of medical
data in the GPRD also presents the possibility of further study of
cancer etiology, morbidity, and survival.
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